(Total Views: 631)
Posted On: 10/18/2017 10:53:44 AM
Post# of 42
This ultra low float stock is brutally undervalued which tradingjust a few pennies above Book Value .Fantastic entry point here this stock is definitely one of the cheapest in the Pharma Sector .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0
As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
https://finance.yahoo.com/news/sonoma-pharmac...00194.html
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
http://pr.report/78EFCjq0
As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
https://finance.yahoo.com/news/sonoma-pharmac...00194.html
(0)
(0)
